Abstract:
Pathogenetic therapy aimed at stopping inflammation in the airways is
the basis of the pharmacotherapy of AD and ACO. An adequate choice of
anti inflammatory (controlling, basic, maintenance) therapy ensures the controllability
of the disease and improves the quality of life of patients. One of the priority
modern directions is the identification of a genetic predisposition to the
development of a particular pathology, including in PBAH. According to the
literature, one of the genetic markers that affect the formation and development of
lung disease is the CYP3A5 cytochrome 450 family gene, in particular its A6986G
polymorphism, due to its direct involvement in CS metabolism.
